Israel Englander Aveo Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.48 - $14.97 $865,112 - $1.53 Million	-102,018 Reduced 67.42%	49,299 $737,000
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $3.25 Million - $4.29 Million	-491,933 Reduced 76.48%	151,317 $1.25 Million
Q2 2022 Aug 15, 2022	SELL	$3.51 - $6.67 $1.44 Million - $2.74 Million	-411,354 Reduced 39.01%	643,250 $4.22 Million
Q1 2022 May 16, 2022	BUY	$3.15 - $6.01 $487,103 - $929,362	154,636 Added 17.18%	1,054,604 $5.9 Million
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $931,870 - $1.47 Million	198,693 Added 28.33%	899,968 $4.22 Million
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $1.13 Million - $1.52 Million	220,290 Added 45.8%	701,275 $4.33 Million
Q2 2021 Aug 16, 2021	BUY	$6.21 - $7.45 $2.91 Million - $3.5 Million	469,384 Added 4046.06%	480,985 $3.17 Million
Q1 2021 May 17, 2021	SELL	$5.97 - $15.28 $435,965 - $1.12 Million	-73,026 Reduced 86.29%	11,601 $85,000
Q4 2020 Feb 16, 2021	BUY	$5.08 - $6.68 $429,905 - $565,308	84,627 New	84,627 $488,000
Q3 2020 Nov 16, 2020	SELL	$4.16 - $6.26 $493,767 - $743,024	-118,694 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $411,868 - $1.19 Million	118,694 New	118,694 $611,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.